Viridian Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -42.3% | -42.3% | -39.0% |
| FY2022 | -32.9% | -32.5% | -29.8% |
| FY2023 | -53.8% | -51.4% | -48.5% |
| FY2024 | -40.2% | -39.0% | -36.4% |
| FY2025 | -47.4% | -47.4% | -38.1% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -42.3% | -42.3% | -39.0% |
| FY2022 | -32.9% | -32.5% | -29.8% |
| FY2023 | -53.8% | -51.4% | -48.5% |
| FY2024 | -40.2% | -39.0% | -36.4% |
| FY2025 | -47.4% | -47.4% | -38.1% |